HEALTH WIRE  /  Depression desk Filed as evergreen · Reviewed for accuracy Coverage: Missouri & the Greater Midwest
Vol. VIISt. Charles County desk
Reader-supported
TheMidwest HealthDispatch
Mental health desk
Info, not adviceVerified against public sources

From our survey

For referrers: coverage and distance top what patients weigh

When a patient leaves your office with an esketamine referral, they run it through a filter you never see. We wanted to know what that filter looks like, so we asked. The answer is less about the treatment than about the logistics around it, and it has direct implications for how referrals should be made.

This is written for primary care physicians and others who refer patients with treatment-resistant depression. Its evidence is a summer questionnaire that 443 working-age respondents finished, drawn from a ten-state Midwest sample, reported as final whole-sample totals.

The filter, ranked

Here is the patient's filter, as our respondents ranked it with two picks apiece:

Insurance did not just lead; more than four in five respondents chose it, nearly double the next factor. Proximity was a solid second. Everything else trailed well behind.

What the ranking says about referrals

The two top factors are precisely the two things a referring clinician is least likely to check. Clinical fit is your domain, and you handle it. Whether the receiving site takes this patient's specific plan, and how far it is from their home, often goes unasked until the patient discovers the answer on the phone.

The consequence is predictable. A clinically sound referral to a site that is out of network, or unreachable for a patient without a driver, fails at the patient's filter even though it passed yours.

Coverage: the dominant screen

Other results reinforce how heavily coverage weighs. For 65 percent of respondents, insurance could settle, or heavily shape, whether they try the treatment. In the tradeoff item, just over half would accept insurance hurdles, 23 percent would hand over cash, and 26 percent could not choose.

The payer mix behind that preference is broad. Respondents were covered by commercial plans (39 percent), Medicaid (37 percent), Medicare (23 percent), and TRICARE (5 percent), with 9 percent uninsured and more than one answer allowed. A referral list that only tracks commercial networks misses much of the population.

Proximity: why it matters more for esketamine

For most specialty referrals, distance is an inconvenience. For esketamine it is structural. The drug is available only at certified treatment centers, patients are observed for at least two hours post-dose, and they may not drive until the next day after restful sleep. The induction phase involves frequent visits.

That turns every mile into a driver's mile, round trip, repeated. Across the Midwest, where rural patients may live far from the nearest certified site, proximity can quietly decide whether a patient completes induction. It is no surprise that 43 percent put it in their top two.

Speed and approval: a closer look

In the forced-choice ranking, FDA approval landed at 27 percent while speed took 24 percent, which might suggest indifference to approval. A standalone question corrects that impression, with 59 percent of respondents rating approval big or decisive.

The likely interpretation is that patients value approval but, limited to two picks, spent them on the constraints that most directly determine access. Some may assume covered care is approved care, which is generally true for esketamine and generally not for off-label ketamine by infusion or at home. That is a distinction worth making explicitly when you refer, since patients frequently conflate the two.

Privacy and specialization: low as screens, relevant for some

Eleven percent ranked privacy in their top two, and 10 percent ranked specialization in veterans or first responders. Only 29 respondents, near 7 percent, were veterans, service members, or first responders themselves. For those patients, trauma experience and familiarity with service culture may matter, and it is reasonable to ask about. But across the sample, these were secondary to coverage and distance.

Your role in the filter

The same survey makes clear that the referrer is the most influential voice in the process. Three respondents in four, 74 percent, said their own doctor is who would persuade them; friends or family drew 18 percent and ads 2 percent. For the opening appointment, 56 percent would book their regular physician, 23 percent a psychiatry practice.

That trust is the reason the logistics matter. A patient who trusts you will try to follow your referral. If it does not survive their coverage and distance filter, they may conclude that the treatment is not for them, rather than that the site was wrong.

Practical steps

Limits

These are results for the full sample. This article reports no breakdown by payer, region, or any other group. As market research on care choices, it offers no clinical evidence on efficacy or suitability, and a patient's fit for esketamine remains your call.

Put 988 in every referral packet, since that number connects to Suicide and Crisis Lifeline staff, spoken or typed, all night and all day, and patients waiting on authorization or scheduling should have it.

Methodology

Source for referrers: study 395586438, run by Pollfish among its panel members until June 23, 2026. There are 443 completes, all adults of working age, living in Ohio, Wisconsin, Nebraska, Missouri, Indiana, Iowa, Minnesota, Illinois, Oklahoma and Kansas. The provider item took two picks and the coverage item several. Overall figures, final. This dispatch's publisher funded and commissioned the work.